Navigation Links
New nanoparticles target cardiovascular disease
Date:1/18/2010

CAMBRIDGE, Mass. Researchers at MIT and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, an advance that potentially provides an alternative to drug-releasing stents in some patients with cardiovascular disease.

The particles, dubbed "nanoburrs" because they are coated with tiny protein fragments that allow them to stick to target proteins, can be designed to release their drug payload over several days. They are one of the first such particles that can precisely home in on damaged vascular tissue, says Omid Farokhzad, associate professor at Harvard Medical School and an author of a paper describing the nanoparticles in the Jan. 18 issue of the Proceedings of the National Academy of Sciences.

Farokhzad and MIT Institute Professor Robert Langer, also an author of the paper, have previously developed nanoparticles that seek out and destroy tumors.

The nanoburrs are targeted to a specific structure, known as the basement membrane, which lines the arterial walls and is only exposed when those walls are damaged. Therefore, the nanoburrs could be used to deliver drugs to treat atherosclerosis and other inflammatory cardiovascular diseases. In the current study, the team used paclitaxel, a drug that inhibits cell division and helps prevent the growth of scar tissue that can clog arteries.

"This is a very exciting example of nanotechnology and cell targeting in action that I hope will have broad ramifications," says Langer.

The researchers hope the particles could become a complementary approach that can be used with vascular stents, which are the standard of care for most cases of clogged and damaged arteries, or in lieu of stents in areas not well suited to them, such as near a fork in the artery.

The particles, which are spheres 60 nanometers in diameter, consist of three layers: an inner core containing a complex of the drug and a polym
'/>"/>

Contact: Jen Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. First metallic nanoparticles resistant to extreme heat
2. Small nanoparticles bring big improvement to medical imaging
3. Nanoparticles used in common household items caused genetic damage in mice
4. Behavior modification could ease concerns about nanoparticles
5. Knocking nanoparticles off the socks
6. Clemson bioengineer uses nanoparticles to target drugs
7. Therapeutic nanoparticles give new meaning to sugar-coating medicine
8. Carbon nanoparticles toxic to adult fruit flies but benign to young
9. New insights into health and environmental effects of carbon nanoparticles
10. Facile synthesis of nanoparticles with multiple functions advanced in Singapore
11. University of Leicester researchers discover new fluorescent silicon nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) ... Market by Product, Application & By Geography - Global ... offering. , This report predicts that the ... by 2020, with an estimated CAGR of 10.6%. ... types such as contact cards & readers, contactless cards ...
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... Many plants can pollinate themselves and reproduce without the aid ... parts. But the short-term perks of being able to go ... in the journal Science . The reason is because ... scientists say. Flowering plants are incredibly creative when it ...
... this study show that fearless behavior in children can ... predisposition. This type of behavior has less correlation ... processes or parenting practice," says Dr. Inbal Kivenson-Baron, who ... fearless behavior also reveal less empathy and more aggression ...
... , Learning a hobby or other complex task in childhood ... the emergence of a personality disorder (PD) later on in ... journal, Development and Psychopathology . Spending time ... or teaching them organizational skills helps to foster better psychological ...
Cached Biology News:Single parenthood doesn't pay off for plants 2Fearless children show less empathy, more aggression 2Play with your kid, for their mental health's sake 2Play with your kid, for their mental health's sake 3
(Date:3/30/2015)... 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a commercial focus on China , ... (CFDA) has approved the Company,s application to conduct a ... carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... and monetization of intellectual property, today provided an ... and  Spherix v. Uniden , Case No. 3:13-cv-03496-M, ... the Northern District of Texas ... Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the United ...
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... 2015  Caris Life Sciences® today announced the ... Intelligence®, the company,s panomic, comprehensive tumor profiling service, ... rare and difficult to treat gynecological cancers may ... to improve patient outcomes. These studies were presented ... of Gynecologic Oncology (SGO) 2015 Annual Meeting on ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4
... Criteria Included a Focus on Research and Respect for ... ... Lilly and Company,(NYSE: LLY ) announced today that it has made ... Science,s 2008 survey polled nearly 4,000 employees from,500 employers in the biotechnology, ...
... Inc.,(Nasdaq: ENMD ) a clinical-stage pharmaceutical company ... diseases,announced today that Thomas H. Bliss, Jr., EntreMed,s ... a Company,overview at the 16th Annual BioPartnering Europe ... London, United Kingdom. Mr. Bliss, presentation,is scheduled for ...
... got a new competitor this week with a stronger and ... team of researchers from four U.S. institutions. , Scientists have ... scurry up walls and cling to ceilings by their toes. ... elastic hairs in their toes that take advantage of atomic-scale ...
Cached Biology Technology:Lilly Recognized as One of the World's Top Biopharmaceutical Employers 2EntreMed to Present at BioPartnering Europe Conference 2EntreMed to Present at BioPartnering Europe Conference 3Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability 2Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability 3Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability 4
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
WTAP Antibody...
Biology Products: